Our programs are focused on providing comprehensive, innovative care with individualized treatments based on each patient’s unique cardiovascular and medical profile. Key aspects of our program include: to ensure an accurate diagnosis, to develop an optimal care plan, to offer access to the newest therapies, to provide education, and to help patients take control of their condition. Of note, we uniquley conduct comprehensive multi-domain health assessments to help guide decision making.
Heart Failure with Preserved Ejection Fraction
The Heart Failure with Preserved Ejection Fraction (HFpEF) Program is one of only a few subspecialty programs in the United States devoted to this challenging subtype of heart failure. Patients with this condition, also known as diastolic heart failure, often experience symptoms like fatigue and shortness of breath despite normal (or preserved) heart pump function. Given the diagnosis and treatment are especially challenging for this complex condition, this underscores the importance of having a dedicated program and committed clinicians. The HFpEF Program seeks to improve outcomes for this vulnerable population.
Cardiac Amyloidosis
The Cardiac Amyloidosis Program seeks to provide a comprehensive, patient-centered treatment plan for patients with cardiac amyloidosis. Amyloidosis is a clinical disorder that occurs when a protein called amyloid builds up in various organs in the body. When amyloid deposits in the heart, it interferes with blood circulation and causes the disease cardiac amyloidosis, leading to heart failure. Early on in cardiac amyloidosis, patients may experience non-specific symptoms and the diagnosis may be mistaken for other conditions like heart disease due to high blood pressure. The best outcome of therapy necessitates early diagnosis as cardiac amyloidosis carries a serious prognosis. We also offer clinical trials to provide our patients access to novel therapies which help suppress the formation of new amyloid as well as manage cardiac-related complications. Our clinical partners include Dr. Cara Rosenbaum (expert in AL amyloidosis), and Dr. Vivian Chin (expert in Amyloid Polyneuropathy).
